会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明授权
    • Ribozymes with linked anchor sequences
    • 具有连锁锚序列的核酶
    • US6080851A
    • 2000-06-27
    • US448446
    • 1995-07-10
    • Catherine J. PachukLeslie R. ConeyFred T. Oakes
    • Catherine J. PachukLeslie R. ConeyFred T. Oakes
    • C12N15/09A61K31/70A61P31/12C07H21/04C12N9/00C12N15/113C12Q1/68
    • C12N15/113C12N15/1135C07K2319/00C12N2310/111C12N2310/121C12N2310/315C12N2310/351C12N2310/353C12N2310/53
    • Ribozymes are provided in which the ribozymes have a catalytic sequence, two legs and at least one anchor sequence complementary to the substrate mRNA at a location noncontiguous with the portions of the substrate mRNA complementary to the legs. In certain preferred embodiments, ribozymes capable of cleaving the L6 mRNA or both the L6 and K28 mRNAs are provided. Methods are provided for the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) patients having the L6 and K28 translocations and, therefore, the L6 mRNA. Additionally, combination treatments comprising components specific for both the K28 and L6 mRNAs are provided. Combination treatments are also provided for those patients which express c-myc in combination with K28 and/or L6 mRNAs. Methods of treatment include, for example, administration of ribozymes and antisense oligonucleotides directed against these mRNAs.
    • PCT No.PCT / US93 / 11144 Sec。 371日期:1995年7月10日 102(e)日期1995年7月10日PCT提交1993年11月16日PCT公布。 出版物WO94 / 13793 日期1994年6月23日提供了这样的酶,其中核酶具有催化序列,两条腿和与底物mRNA互补的位置与底物mRNA互补的至少一个锚定序列。 在某些优选实施方案中,提供能够切割L6 mRNA或L6和K28 mRNA两者的核酶。 提供了用于治疗慢性骨髓性白血病(CML)和具有L6和K28易位的急性淋巴细胞性白血病(ALL)患者以及L6mRNA的方法。 另外,提供包含对K28和L6 mRNA特异性成分的组合处理。 还为那些表达c-myc与K28和/或L6mRNA组合的患者提供组合治疗。 治疗方法包括例如施用针对这些mRNA的核酶和反义寡核苷酸。
    • 15. 发明授权
    • Phenalenimine fluorescent dyes and their use in analytical compositions,
elements and methods
    • 苯亚胺荧光染料及其在分析组合物,元素和方法中的应用
    • US5154887A
    • 1992-10-13
    • US705874
    • 1991-05-28
    • Bruce E. BabbFred T. Oakes
    • Bruce E. BabbFred T. Oakes
    • C09B55/00G01N33/533
    • G01N33/533C09B55/009Y10S435/805
    • Certain phenalenimine fluorescent compounds represented by the structure ##STR1## wherein R' and R" are independently hydrogen, alkyl, cycloalkyl, aryl or a heterocycle, or R' comprises the carbon and heteroatoms which form a fused ring with the compound nucleus, are useful in biomedical and analytical determinations. These compounds can be used for staining cells, as well as for the determination of various analytes found in human or animal biological fluids. Such determinations can be carried out in solution or by using dry analytical elements. The fluorescent compounds can be reacted with quinone nuclei to form reducible compounds which are also useful in analytical methods. In addition, the compounds can be incorporated into what are known as "loadable" latex particles to form detectable labels and biological reagents.
    • 由结构表示的某些吩噻嗪类荧光化合物,其中R'和R“独立地是氢,烷基,环烷基,芳基或杂环,或R'包括与化合物核形成稠合环的碳和杂原子 可用于生物医学和分析测定。 这些化合物可用于染色细胞,以及用于测定在人或动物生物流体中发现的各种分析物。 这种测定可以在溶液中或通过使用干燥的分析元件进行。 荧光化合物可与醌核反应形成可还原的化合物,也可用于分析方法。 此外,化合物可以掺入所谓的“可装载”胶乳颗粒中以形成可检测的标记物和生物试剂。